Berta Sousa

Aug 9, 2024 | cancernetwork.com | Lowell L Hart |Seock-Ah Im |Sara M. Tolaney |Mario Campone |Timothy J. Pluard |Berta Sousa | +6 more

BackgroundRibociclib plus endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA (ML) trials in patients with hormone receptor–positive/HER2-negative (HER2+/HER2–) advanced breast cancer (ABC). Here, we report efficacy, safety, and quality of life in elderly patients in the ML trials. MethodsData were pooled from ML-2, -3, and -7 for patients treated with ribociclib plus ET or placebo plus ET.